RadioShack Corp. $300 Million Senior Unsecured Notes Rated 'A-'

  • ID: 1751149
  • May 2001
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

NEW YORK (Standard & Poor's CreditWire) May 4, 2001--Standard & Poor's today assigned its single-'A'-minus rating to RadioShack Corp.'s proposed $300 million senior unsecured note issue due in 2011 and issued under Rule 144A with registration rights. At the same time, Standard & Poor's affirmed its single-'A'-minus long-term corporate credit and senior unsecured debt ratings on RadioShack. The 'A-2' short-term corporate credit and commercial paper ratings on the company were also affirmed. The outlook is stable. Proceeds from the new debt offering will be used to repay short-term debt. The ratings on RadioShack reflect the strong cash flow and profitability of the RadioShack store network. This factor is mitigated by the company's exposure to consumer electronic product cycles, a competitive...

Companies mentioned in this report are: RadioShack Corp.
Action: New Rating

Note: Product cover images may vary from those shown
2 of 3

RadioShack Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.